AgomAb Therapeutics NV (AGMB) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $8.28, -0.60% vs the prior close of $8.33.
- Volume 78.13K shares, 0.5x its 50-day average (light).
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
AGMB dips 0.6% to $8.28, a 6-month low, 4 down days in a row. Closed at $8.28, -0.60% vs the prior close of $8.33. Day range $7.92–$8.53, opened at $8.21.
AGMB daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — AGMB dips 0.6% to $8.28, a 6-month low, 4 down days in a row
- Closed at $8.28, -0.60% vs the prior close of $8.33. Day range $7.92–$8.53, opened at $8.21.
- Volume was 78.13K shares, 0.5x its 50-day average of 158.09K — lighter than usual.
- Price is -31.2% vs its 50-day average ($12.03).
- 52-week range $7.92–$17.82; today's close sits at 4% of that range, 53.5% below the 52-week high.
- That makes 4 straight losses.
Oct 15, 2026 — AGMB slides 4.1% to $8.33, a 6-month low, 3 down days in a row
- Closed at $8.33, -4.14% vs the prior close of $8.69. Day range $8.15–$8.86, opened at $8.56.
- Volume was 97.70K shares, 0.6x its 50-day average of 156.72K.
- Price is -31.3% vs its 50-day average ($12.13).
- 52-week range $7.97–$17.82; today's close sits at 4% of that range, 53.3% below the 52-week high.
- That makes 3 straight losses.
Oct 14, 2026 — AGMB dips 1.4% to $8.69
- Closed at $8.69, -1.36% vs the prior close of $8.81. Day range $8.51–$9.08, opened at $8.80.
- Volume was 57.70K shares, 0.4x its 50-day average of 157.31K — lighter than usual.
- Price is -29.1% vs its 50-day average ($12.25).
- 52-week range $7.97–$17.82; today's close sits at 7% of that range, 51.2% below the 52-week high.
Oct 13, 2026 — AGMB slides 3.1% to $8.81
- Closed at $8.81, -3.08% vs the prior close of $9.09. Day range $8.73–$9.35, opened at $9.05.
- Volume was 59.40K shares, 0.4x its 50-day average of 158.64K — lighter than usual.
- Price is -28.8% vs its 50-day average ($12.37).
- 52-week range $7.97–$17.82; today's close sits at 9% of that range, 50.6% below the 52-week high.
- SEC filings that day: 6-K.
Oct 12, 2026 — AGMB ends flat (+0.1%) to $9.09
- Closed at $9.09, +0.11% vs the prior close of $9.08. Day range $9.05–$9.65, opened at $9.18.
- Volume was 62.30K shares, 0.4x its 50-day average of 158.48K — lighter than usual.
- Price is -27.1% vs its 50-day average ($12.47).
- 52-week range $7.97–$17.82; today's close sits at 11% of that range, 49.0% below the 52-week high.
Oct 9, 2026 — AGMB dips 1.5% to $9.08
- Closed at $9.08, -1.52% vs the prior close of $9.22. Day range $8.92–$9.49, opened at $9.36.
- Volume was 102.10K shares, 0.6x its 50-day average of 157.81K.
- Price is -27.6% vs its 50-day average ($12.54).
- 52-week range $7.97–$17.82; today's close sits at 11% of that range, 49.0% below the 52-week high.
Oct 8, 2026 — AGMB jumps 4.8% to $9.22
- Closed at $9.22, +4.77% vs the prior close of $8.80. Day range $8.56–$9.45, opened at $8.88.
- Volume was 225.20K shares, 1.5x its 50-day average of 154.25K.
- Price is -26.9% vs its 50-day average ($12.62).
- 52-week range $7.97–$17.82; today's close sits at 13% of that range, 48.3% below the 52-week high.
Oct 7, 2026 — AGMB dips 0.5% to $8.80
- Closed at $8.80, -0.45% vs the prior close of $8.84. Day range $8.68–$9.35, opened at $8.95.
- Volume was 104.90K shares, 0.7x its 50-day average of 152.81K.
- Price is -30.6% vs its 50-day average ($12.68).
- 52-week range $7.97–$17.82; today's close sits at 8% of that range, 50.6% below the 52-week high.
Oct 6, 2026 — AGMB rises 1.7% to $8.84
- Closed at $8.84, +1.73% vs the prior close of $8.69. Day range $8.40–$8.97, opened at $8.77.
- Volume was 103.90K shares, 0.7x its 50-day average of 151.40K.
- Price is -30.7% vs its 50-day average ($12.76).
- 52-week range $7.97–$17.82; today's close sits at 9% of that range, 50.4% below the 52-week high.
Oct 5, 2026 — AGMB rises 1.5% to $8.69
- Closed at $8.69, +1.52% vs the prior close of $8.56. Day range $7.97–$8.71, opened at $8.51.
- Volume was 129.60K shares, 0.9x its 50-day average of 149.99K.
- Price is -32.3% vs its 50-day average ($12.83).
- 52-week range $7.97–$17.82; today's close sits at 7% of that range, 51.2% below the 52-week high.
Oct 2, 2026 — AGMB dips 1.0% to $8.56, a 6-month low on 2.7x normal volume
- Closed at $8.56, -1.04% vs the prior close of $8.65. Day range $8.00–$9.34, opened at $8.65.
- Volume was 388.70K shares, 2.7x its 50-day average of 144.86K — unusually heavy trading.
- Price is -33.7% vs its 50-day average ($12.91).
- 52-week range $8.00–$17.82; today's close sits at 6% of that range, 52.0% below the 52-week high.
AGMB latest news & SEC filings
Every SEC filing by or about AGMB in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 13, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Oct 9, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Epstein David R bought 5,000 shares at $8.90 (≈$44.50K) on Oct 8, 2026; now holds 15,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Epstein David R bought 5,000 shares at $8.57 (≈$42.85K) on Oct 5, 2026; now holds 5,000
- Epstein David R bought 5,000 shares at $8.70 (≈$43.50K) on Oct 6, 2026; now holds 10,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kemula Pierre Thadee Victor bought 3,000 shares at $8.67 (≈$26.01K) on Oct 6, 2026; now holds 3,000
- Kemula Pierre Thadee Victor bought 5,000 shares at $8.57 (≈$42.85K) on Oct 6, 2026; now holds 8,000
- Kemula Pierre Thadee Victor bought 2,000 shares at $8.54 (≈$17.08K) on Oct 6, 2026; now holds 10,000
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 7, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Knotnerus Tim Jasper bought 6,000 shares at $8.48 (≈$50.88K) on Oct 5, 2026; now holds 16,823
- Knotnerus Tim Jasper bought 5,000 shares at $8.70 (≈$43.50K) on Oct 6, 2026; now holds 21,823
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Oct 1, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 15, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Sep 14, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Sep 11, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 10, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Aug 6, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Jun 23, 2026 · Form 6-K — Report from a foreign company (6-K)
Report from a foreign company (6-K) — news it published at home
Things to know before you trade AGMB
- How much it moves: over the last 20 sessions the average daily move was 3.41% (largest 22.1%). That is a volatile stock.
- Liquidity: about 145.25K shares (≈$1.20M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $8.28 vs a range of $7.92–$17.82 (4% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 0 open-market buys, 0 sales.
- Latest filings: 6-K Oct 13, 2026; 6-K Oct 1, 2026; 6-K Sep 14, 2026.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
AGMB market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 8.21 | 8.53 | 7.92 | 8.28 | 78.13K |
| Oct 15, 2026 | 8.56 | 8.86 | 8.15 | 8.33 | 97.70K |
| Oct 14, 2026 | 8.80 | 9.08 | 8.51 | 8.69 | 57.70K |
| Oct 13, 2026 | 9.05 | 9.35 | 8.73 | 8.81 | 59.40K |
| Oct 12, 2026 | 9.18 | 9.65 | 9.05 | 9.09 | 62.30K |
| Oct 9, 2026 | 9.36 | 9.49 | 8.92 | 9.08 | 102.10K |
| Oct 8, 2026 | 8.88 | 9.45 | 8.56 | 9.22 | 225.20K |
| Oct 7, 2026 | 8.95 | 9.35 | 8.68 | 8.80 | 104.90K |
| Oct 6, 2026 | 8.77 | 8.97 | 8.40 | 8.84 | 103.90K |
| Oct 5, 2026 | 8.51 | 8.71 | 7.97 | 8.69 | 129.60K |
| Oct 2, 2026 | 8.65 | 9.34 | 8.00 | 8.56 | 388.70K |
| Oct 1, 2026 | 11.21 | 11.32 | 8.56 | 8.65 | 639.20K |
| Sep 30, 2026 | 10.62 | 11.36 | 10.58 | 11.10 | 133.70K |
| Sep 29, 2026 | 10.23 | 10.69 | 10.14 | 10.53 | 113.50K |
| Sep 28, 2026 | 10.51 | 10.54 | 9.87 | 10.21 | 147.20K |
| Sep 25, 2026 | 10.65 | 11.23 | 10.41 | 10.51 | 164.00K |
| Sep 24, 2026 | 10.75 | 10.99 | 10.50 | 10.58 | 64.20K |
| Sep 23, 2026 | 11.54 | 11.80 | 10.64 | 10.77 | 98.70K |
| Sep 22, 2026 | 11.70 | 11.85 | 11.31 | 11.49 | 49.40K |
| Sep 21, 2026 | 12.26 | 12.26 | 11.28 | 11.70 | 85.40K |
About AgomAb Therapeutics NV
AgomAb Therapeutics NV (AGMB) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in ANTWERPEN. State of incorporation: Belgium. Fiscal year ends December 31. SEC CIK 2020932.
AGMB board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Colin Michael Bond | Director | Mar 18, 2026 |
| David R Epstein | Director | Mar 18, 2026 |
| Marino Garcia | Director | Sep 15, 2026 |
| Ohad Hammer | Director | Mar 18, 2026 |
| Angelika Martha Jahreis | Director | Mar 18, 2026 |
| Tim Jasper Knotnerus | Chief Executive Officer | Mar 18, 2026 |
| Naimish Patel | Director | Sep 15, 2026 |
| Weegen Felice Isabel Verduyn-Van | Director | Mar 18, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Andrea Saez Borderias | Chief Development Officer | Mar 18, 2026 |
| Pierre Thadee Victor Kemula | Chief Financial Officer | Mar 18, 2026 |
| Tim Jasper Knotnerus | Chief Executive Officer | Mar 18, 2026 |
| Ellen Lefever | General Counsel | Mar 18, 2026 |
| Philippe Constantin Wiesel | Chief Medical Officer | Mar 18, 2026 |
| Der Horst Paul Henryk Van | Chief Business Officer | Mar 18, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| No open-market insider buys or sales reported in the last 12 months. | ||||
AGMB financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| No annual XBRL figures available (foreign filers often report on Form 20-F). | ||||
Latest balance sheet: total assets $—, total liabilities $—, cash $—.
AGMB earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| No 8-K earnings releases in recent filings. | ||
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on AGMB
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.